Choosing Topical Corticosteroids JONATHAN D

Total Page:16

File Type:pdf, Size:1020Kb

Choosing Topical Corticosteroids JONATHAN D Choosing Topical Corticosteroids JONATHAN D. FERENCE, PharmD, Nesbitt College of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, Pennsylvania ALLEN R. LAST, MD, MPH, Racine Family Medicine Residency Program, Medical College of Wisconsin, Racine, Wisconsin Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions. There are many topical steroids available, and they differ in potency and formulation. Successful treatment depends on an accurate diagnosis and consideration of the steroid’s delivery vehicle, potency, frequency of application, duration of treatment, and side effects. Although use of topical steroids is common, evidence of effectiveness exists only for select condi- tions, such as psoriasis, vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, and lichen sclero- sus. Evidence is limited for use in melasma, chronic idiopathic urticaria, and alopecia areata. (Am Fam Physician. 2009;79(2):135-140. Copyright © 2009 American Academy of Family Physicians.) opical steroids are available in a Indications variety of potencies and prepara- An accurate diagnosis is essential when tions. Physicians should become selecting a steroid. A skin scraping and familiar with one or two agents in potassium hydroxide test can clarify whether T each category of potency to safely and effec- a steroid or an antifungal is an appropriate tively treat steroid-responsive skin condi- choice, because steroids can exacerbate a tions. When prescribing topical steroids, fungal infection. Topical corticosteroids are it is important to consider the diagnosis effective for conditions that are character- as well as steroid potency, delivery vehicle, ized by hyperproliferation, inflammation, frequency of administration, duration of and immunologic involvement. They can treatment, and side effects. The useful- also provide symptomatic relief for burning ness and side effects of topical steroids are and pruritic lesions. a direct result of their anti-inflammatory Many skin conditions are treated with properties, although no single agent has topical steroids (Table 1), but evidence of been proven to have the best benefit-to-risk effectiveness has been established only for ratio. a small number of conditions. For example, high- or ultra-high-potency topical steroids, alone or in combination with other topical Table 1. Conditions Treatable with Topical Steroids treatments, are the mainstay of therapy for psoriasis.1 They are also effective for treating High-potency steroids (groups I to III) Atopic dermatitis vitiligo involving a limited area of a patient’s Alopecia areata Lichen sclerosus (vulva) skin,2,3 lichen sclerosus,4 bullous pemphi- Atopic dermatitis (resistant) Nummular eczema goid, and pemphigus foliaceus.5,6 Alopecia Discoid lupus Scabies (after scabicide) areata, which is usually self-limited, may Hyperkeratotic eczema Seborrheic dermatitis respond to ultra-high-potency topical corti- Lichen planus Severe dermatitis costeroids, but randomized controlled trials Lichen sclerosus (skin) Severe intertrigo (short-term) have yielded conflicting results.7,8 Lichen simplex chronicus Stasis dermatitis Medium- to high-potency topical cortico- Nummular eczema Low-potency steroids steroids are effective for atopic dermatitis and Poison ivy (severe) (groups VI and VII) 9,10 Psoriasis Dermatitis (diaper) eczema in adults and children, as well as 11,12 Severe hand eczema Dermatitis (eyelids) for phimosis (i.e., foreskin that cannot be 13,14 Medium-potency steroids Dermatitis (face) retracted) and acute radiation dermatitis. (groups IV and V) Intertrigo Topical corticosteroids may be effective for Anal inflammation (severe) Perianal inflammation other conditions, but the data to support their Asteatotic eczema use are from small, low-level, or uncorrobo- rated studies. Melasma,15 chronic idiopathic January 15, 2009 ◆ Volume 79, Number 2 www.aafp.org/afp American Family Physician 135 Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright © 2009 American Academy of Family Physicians. For the private, noncommercial use of one individual user of the Web site. All other rights reserved. Contact [email protected] for copyright questions and/or permission requests. SORT: KEY RECOMMENDATIONS FOR PRACTICE Evidence Clinical recommendation rating References Topical steroids can be used to treat psoriasis, vitiligo, lichen sclerosus, atopic dermatitis, eczema, and C 1, 2, 4, 9-13 acute radiation dermatitis. Ultra-high-potency topical steroids should not be used continuously for longer than three weeks. C 21 Low- to high-potency topical steroids should not be used continuously for longer than three months to C 21 avoid side effects. Combinations of topical steroids and antifungal agents generally should be avoided to reduce the risk C 31 of tinea infections. A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease- oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp. org/afpsort.xml. urticaria,16 infantile acropustulosis,17 prepubertal labial Because hydration generally promotes steroid pen- adhesions,18 and transdermal testosterone-patch–induced etration, applying a topical steroid after a shower or skin irritation19 fall into this category. bath improves effectiveness.20 Occlusion increases ste- roid penetration and can be used in combination with Steroid Vehicles all vehicles. Simple plastic dressings (e.g., plastic wrap) Steroids may differ in potency based on the vehicle in result in a several-fold increase in steroid penetration which they are formulated. Some vehicles should be used compared with dry skin.21 Occlusive dressings are often only on certain parts of the body. Ointments provide used overnight and should not be applied to the face or more lubrication and occlusion than other preparations, intertriginous areas. Irritation, folliculitis, and infec- and are the most useful for treating dry or thick, hyper- tion can develop rapidly from occlusive dressings, and keratotic lesions. Their occlusive nature also improves patients should be counseled to monitor the treatment steroid absorption. Ointments should not be used on site closely. Flurandrenolide (Cordran) 4 mcg per m2 hairy areas, and may cause maceration and folliculitis impregnated dressing is formulated to provide occlu- if used on intertriginous areas (e.g., groin, gluteal cleft, sion. It is beneficial for treating limited areas of inflam- axilla). Their greasy nature may result in poor patient mation in otherwise difficult-to-treat locations, such as satisfaction and compliance. fingertips. Creams are mixes of water suspended in oil. They have good lubricating qualities, and their ability to van- Potency ish into the skin makes them cosmetically appealing. The preferred way to determine topical steroid potency Creams are generally less potent than ointments of the is the vasoconstrictor assay, which classifies steroids same medication, and they often contain preservatives, based on the extent to which the agent causes cutaneous which can cause irritation, stinging, and allergic reac- vasoconstriction (“blanching effect”) in normal, healthy tion. Acute exudative inflammation responds well to persons. This is a useful but imperfect method for pre- creams because of their drying effects. Creams are also dicting the clinical effectiveness of steroids.21 The anti- useful in intertriginous areas where ointments may not inflammatory potency of some steroids may vary among be used. However, creams do not provide the occlusive patients, depending on the frequency of administration, effects that ointments provide. the duration of treatment, and where on the body they Lotions and gels are the least greasy and occlusive are used.22,23 A ranking system that compares clinical of all topical steroid vehicles. Lotions contain alco- outcomes or an effectiveness-to-safety ratio may be of hol, which has a drying effect on an oozing lesion. greater benefit, but does not currently exist. Lotions are useful for hairy areas because they pene- There are seven groups of topical steroid potency, trate easily and leave little residue. Gels have a jelly-like ranging from ultra high potency (group I) to low potency consistency and are beneficial for exudative inflamma- (group VII). Table 2 provides a list of topical steroids and tion, such as poison ivy. Gels dry quickly and can be available preparations listed by group, formulation, and applied on the scalp or other hairy areas and do not generic availability.24 Brand name agents may be more cause matting. expensive, which may reduce patient compliance. This Foams, mousses, and shampoos are also effective vehi- should be considered when choosing steroid agents. Phy- cles for delivering steroids to the scalp. They are easily sicians should also be aware that some generic formula- applied and spread readily, particularly in hairy areas. tions have been shown to be less or more potent than Foams are usually more expensive. their brand-name equivalent.25 136 American Family Physician www.aafp.org/afp Volume 79, Number 2 ◆ January 15, 2009 Table 2. Potency Ratings of Topical Corticosteroids Medication Potency (group) Generic Brand Dosage vehicle Available sizes Ultra high (I) Augmented betamethasone Diprolene* G,† O 15, 45, 50 g dipropionate 0.05% Clobetasol propionate 0.05% Clobex L, Sh 59, 118 mL (L);
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Triamcinolone Acetonide Cream USP, 0.025%, 0.1%, 0.5% for Dermatologic Use Only Not for Ophthalmic Use Rx Only
    TRIAMCINOLONE ACETONIDE- triamcinolone acetonide cream Padagis Israel Pharmaceuticals Ltd ---------- Triamcinolone Acetonide Cream USP, 0.025%, 0.1%, 0.5% For Dermatologic Use Only Not For Ophthalmic Use Rx Only DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti- inflammatory and anti-pruritic agents. Triamcinolone acetonide is designated chemically as pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis (oxy)]-,(11ß,16α)-. C24H31FO6, and M.W. of 434.51; CAS Reg. No. 76-25-5. Each gram of 0.025%, 0.1% and 0.5% Triamcinolone Acetonide Cream USP contains 0.25 mg, 1 mg, or 5 mg triamcinolone acetonide respectively, in a washable cream base of cetyl alcohol, cetyl esters wax, glycerin, glyceryl monostearate, isopropyl palmitate, polysorbate-60, propylene glycol, purified water, sorbic acid, and sorbitan monostearate. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Audaval 0.1% Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 1 mg of betamethasone (0.1% w/w) as valerate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment Opaque ointment. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Audaval preparations are indicated for the treatment of: eczema in children over 1 year elderly and adults; including atopic and discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma. In general, ointment preparations are particularly appropriate for dry, lichenified or scaly skin conditions whereas a cream preparation may be more suitable in the case of moist or weeping lesions. 4.2 Posology and method of administration For topical use only. If no improvement is seen after two to four weeks, the diagnosis should be reconsidered and specialist referral may be necessary. Adults, adolescents and the elderly A small quantity of Audaval should be applied to the affected area one to three times daily as directed by physician until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often, or by using the appropriate ready diluted (1 in 4) preparation, Audaval RD 0.025% Ointment. Allow adequate time for absorption after each application before applying an emollient. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis
    THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie Arsonnaud Owing to its anti-inflammatory, antipruritic, soriasis is a lifelong condition, with onset vasoconstrictive, and immune-modulating prop- occurring at any time throughout life. It erties, clobetasol propionate is used to treat P affects men and women equally, and almost all psoriasis. This study was conducted to evaluate races in varying rates of frequency are affected. Pso- the efficacy, safety, and cosmetic acceptability riasis usually first appears between the ages of 15 of clobetasol propionate lotion compared with and 30 years and may occur anywhere on the body. its vehicle and with clobetasol propionate Psoriasis is an inherited condition; however, cream in the treatment of moderate to severe both genetic and environmental factors play an plaque-type psoriasis. important role in its onset and course. The condi- A total of 222 patients were treated. After tion has a considerable impact on quality of life, 4 weeks of treatment, clobetasol propionate with patients complaining about the messiness of lotion was more efficient than vehicle lotion and the topical agents used to treat the condition and of equivalent efficacy as clobetasol propionate the profound psychological impact of the treat- cream. Cosmetic acceptability was significantly ments and the condition.1-5 better with clobetasol propionate lotion than with Clobetasol propionate is known for its anti- clobetasol propionate cream. Clobetasol propi- inflammatory, antipruritic, vasoconstrictive, and onate lotion was efficient, safe, and well toler- immune-modulating properties and is currently ated and offers a significantly higher cosmetic used in the treatment of certain hyperproliferative advantage in the treatment of moderate to or inflammatory dermatoses, including psoriasis severe plaque-type psoriasis compared with and atopic dermatitis.
    [Show full text]
  • Drugs That Are Not Covered
    Drugs that are Not Covered* Current 10/1/21 In addition to this list, newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee has had an opportunity to review the medication, to determine whether the medication will be covered and if so, which tier will apply based on safety, efficacy and the availability of other products within that class of medications. The current list of newly marketed drugs can be found on our New to Market Drug list. Abilify tablets albuterol HFA inhalers (authorized Apexicon E cream Abilify MyCite tablets generics for ProAir, Proventil, Ventolin Apidra vials Absorica capsules HFA inhalers) Apidra SoloStar injection Absorica LD capsules Aldactone tablets Aplenzin tablets Abstral sublingual tablets Aldara cream Apriso capsules Acanya gel and pump gel Alkindi sprinkle capsules Arava tablets Accupril tablets Allegra Children’s Allergy ODT Arazlo lotion acetaminophen 320.5 mg/caffeine 30 Allegra ODT, suspension and tablets Arestin microspheres mg/dihydrocodeine 16 mg Alltizal tablets Aricept tablets capsulesAciphex tablets alogliptin (authorized generic for Aricept ODT Aciphex Sprinkle capsules Nesina) Arimidex tablets Acticlate tablets alogliptin/metformin tablets (authorized Arixtra injection Active-Prep kits generic for Kazano) ArmonAir Digihaler inhaler Activella tablets alogliptin/pioglitazone (authorized ArmonAir Respiclick inhaler Actonel tablets generic for Oseni) Aromasin tablets Actoplus Met tablets Alphagan P 0.1% eye drops Arthrotec 50 and 75 tablets Actos
    [Show full text]
  • A List of Medications That May Lower Your Patients' Costs
    A list of medications that may lower your patients’ costs INTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically sound and that it supports patient health. This committee reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. FORMULARY DESIGN There are numerous formulary designs that can be used by a pharmacy benefits administrator. Catamaran has chosen a formulary structure which is open and incentive based. Open Formulary: features co‐payments for medications that are preferred and non‐ preferred brands, plus lower co‐payments for generic drugs. Incentive Based: features different co‐payments for medications that are on or off the formulary. In this type of formulary, the patient cost structure may be two‐tier, three‐ tier, or four‐tier design. USING THIS FORMULARY REFERENCE GUIDE TO HELP CONTAIN COSTS Many benefit sponsors use the Catamaran formulary to help manage the overall cost of providing prescription drug benefits. This formulary offers a wide range of medications from which to choose. We realize that this formulary reference guide may not include every drug from every manufacturer. However, choosing a preferred drug when it is appropriate can provide access to the necessary medications to stay healthy, at a cost that is more affordable. KNOWING HOW THE FORMULARY INFORMATION IS ORGANIZED The following formulary reference guide is designed so that generic products are listed first in each drug category. The preferred brand name products are listed next, and non‐preferred brand products are listed last.
    [Show full text]
  • Product Monograph Cyclocort
    PRODUCT MONOGRAPH PrCYCLOCORT® amcinonide USP Cream, USP 0.1% w/w Ointment, USP 0.1% w/w Lotion 0.1% w/w Topical Corticosteroid GlaxoSmithKline Inc. Date of Revision: 7333 Mississauga Road November 4, 2014 Mississauga, Ontario L5N 6L4 www.stiefel.ca Submission Control No: 175944 ©2014 GlaxoSmithKline Inc., All Rights Reserved ®CYCLOCORT is a registered trade-mark owned by GlaxoSmithKline Inc. November 4, 2014 Page 1 of 17 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION.................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 8 DRUG INTERACTIONS ............................................................................................... 8 DOSAGE AND ADMINISTRATION ........................................................................... 9 OVERDOSAGE ........................................................................................................... 11 STORAGE AND STABILITY ..................................................................................... 11 SPECIAL HANDLING INSTRUCTIONS
    [Show full text]
  • Dry Skin Eczema
    Dry Skin/Eczema 1. Avoid irritating factors in soaps, detergents, fabric softeners, dryer sheets, dyes, or perfumes. Be sure all products are scent and dye free (read labels!). Examples Include: Detergent – All Free & Clear, Dreft Skin Cleanser – Cetaphil, CeraVe Hydrating Cleanser, Aquaphor (wash), Aveeno Eczema Wash Moisturizer – Vaseline, Aquaphor, CeraVe, Cetaphil Restoraderm, Aveeno Eczema Cream, or even some natural oils (i.e. coconut oil, however keep in mind some may be allergic to this) 2. Give a SHORT daily lukewarm bath of 5-10 minutes with a mild skin cleanser. Don’t rub with a washcloth – this can lead to irritation. Remember that water is actually drying to our skin (it can remove the essential oils that protect us from dryness). 3. Immediately after the bath, pat the child relatively dry, then apply ointment or cream generously from head to toe. In children with eczema, one of the most important steps in their care is using moisturizers; this must be done multiple times every day for best results. 4. When the child is itchy/scratching give Claritin (OTC) or Zyrtec (OTC) in the morning and give Benadryl (OTC) or Atarax (Prescription) at night. 5. Trim nails on a regular basis to minimize scratch injury. Put gloves on at night for severe scratches. 6. Remember that eczema is a chronic condition and will come and go for several months/years. Our goal is to get it under control, but the child who has this predisposition will probably always need a little “extra moisture” and skin care. Also, getting viral infections or fevers or other illnesses as well changes in weather or certain foods might precipitate an outbreak of eczema temporarily.
    [Show full text]